EUCTR2010-023335-41-AT进行中（未招募）不适用
A Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed Indolent Lymphoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Abbott
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Relapsed indolent b-cell lymphoma with ECOG performance status = 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. Diagnosis of grade 3b follicular lymphoma or transformed lymphoma
- •2. Refractory to bendamustine
- •3. Discontinued rituximab due to toxicity
研究者
相似试验
已完成
不适用
Targeted therapy in patients with advanced pancreatic cancerAdvanced pancreatic cancer (stage IVb)Pancreatic cancerCancerISRCTN70474205Roche Pharma AG (Germany)37
已完成
2 期
Phase II study of Trastuzuman in combination with TS-1 and Cisplatin for patients with Human Epidermal Growth Facter Receptor type-2 (HER-2)-positive Advanced Gastric CancerGastric cancerJPRN-UMIN000008389West Japan Oncology Group55
已完成
不适用
Phase II study of a combination of TS-1 and TXL for advanced/recurrent gastric cancer patients with peritoneal metastasisPatients with gastric cancer and peritoneal metastasisJPRN-UMIN000000746OGSG30
未知
2 期
An early phase II study of TSU-68 in combination with docetaxel in patients with advanced and metastatic breast cancer progressing anthracycline containing regimen.Breast cancerJPRN-jRCT2080221143Taiho Pharmaceutical Co., Ltd.19
招募中
不适用
Additional TR study on Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinomaHER2 positive gastric and gastroesophageal junction adenocarcinomaJPRN-jRCT1030210361Shitara Kohei37